ClinicalTrials.gg
RecruitingNCT06831032EASYUpdated Oct 20, 2026

Elective Adaptive Radiation With SBRT for Improved DurabilitY of Response

An interventional study of Adaptive radiotherapy using SBRT in Prostate Adenocarcinoma, Iliac Nodal Disease and Para-aortic Lymph Node Metastasis, sponsored by University Health Network, Toronto. Recruiting at 1 site in Canada. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-20.

Sponsored by University Health Network, Toronto · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.
Updated Oct 20, 2026Start date movedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
26
Allocation
Not applicable
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 36 studies in Neoplasm Metastasis by University Health Network, Toronto — 10 open to participants now, 15 under way, 2 of them phase 3. Neoplasm Metastasis · University Health Network, Toronto.

Planned enrollment
11th of 27
26 · median 25
Started
2026
with 1 other
No phase
6 of 36
2 open now
Primary completion
2029-04
later than 9 of 14 live
Registered
35th of 36
by date

Among the 36 studies in Neoplasm Metastasis by University Health Network, Toronto, this one is the 11th largest by planned enrollment of the 27 interventional ones that give a count, is one of 2 that started in 2026, is one of 6 with no phase, reaches primary completion later than 9 of the 14 other live ones, and was the 35th registered.

Neoplasm Metastasis

4,052 studies on the registry are indexed under Neoplasm Metastasis; 891 are open to participants now.

Browse Neoplasm Metastasis studies →

Open to participants now

10 of the 36 studies in Neoplasm Metastasis by University Health Network, Toronto are open now, in 1 country. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 10 open studies →

Where they have run

Who these studies take

Of the 692 Neoplasm Metastasis studies recruiting now, 539 (78%) set no upper age limit and 96 (14%) stop at 75 or younger; 47 take children under 18; 18 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies in Neoplasm Metastasis by University Health Network, Toronto, or all of them as a file.
02

Study summary

This prospective, single-arm feasibility study will include patients with prostate cancer that have controlled local disease diagnosed with oligorecurrent para-aortic nodal disease and/or common iliac nodal disease detected by PSMA PET or conventional CT/MRI imaging, and these patients will undergo CT-guided online adaptive SBRT to the tumor and elective SBRT to adjacent at-risk nodal regions.

03

Conditions studied

  • Prostate Adenocarcinoma
  • Iliac Nodal Disease
  • Para-aortic Lymph Node Metastasis
  • Para-aortic Nodal Disease
  • Oligorecurrence

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. confirmed prostate adenocarcinoma.
  2. Oligorecurrent para-aortic +/- common iliac nodal disease planned for SBRT.
  3. ≤10 involved para-aortic (defined as between L1/L2 interface and L4/L5 interface) +/- common iliac LN on PSMA PET imaging.
  4. performance status 0-2.

Exclusion criteria

Exclusion Criteria:

  1. Prior radiotherapy to the nodal echelon (PA +/- common iliac).
  2. Active secondary , except for adequately treated non-melanoma skin cancer.
  3. Presence of significant comorbidities or medical conditions that may compromise the ability to undergo radiotherapy or participate in the study.
  4. to radiation.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
26 participants (estimated)

Study arms

  • Experimental
    SBRT delivered with CBCT-guided online adaptive RT

    Patients will undergo CT guided online adaptive SBRT 30-40Gy to the tumor nodal GTV volume(s) plus 25Gy in 5 fractions ENI to PA nodes (+/- pelvic nodes).

    Radiation: Adaptive radiotherapy using SBRT

Interventions

  • RadiationAdaptive radiotherapy using SBRT

    Adaptive External beam radiotherapy using SBRT 30-40Gy to the tumor nodal GTV volume(s) plus 25 Gy in 5 fractions ENI to PA nodes (+ common iliac nodes)

06

What researchers measure

Primary outcomes

  1. Quantify adverse events using CTCAE v5.0

    Acute toxicities (≤3 months) and long-term toxicities (related to urinary, bowel or sexual function) will be collected and evaluated by the CTCAE v5.0.

    Time frame: 2 years

Secondary outcomes

  1. QoL using EPIC questionnaire

    Quality of life (QOL) will be collected using expanded prostate cancer index composite (EPIC) questionnaire. The quality-of-life scores will be converted to a scale of 0-100 for each category. A higher score indicates a better quality of life.

    Time frame: 2 years

  2. Pain levels using EPIC questionnaire

    Pain levels will be collected using expanded prostate cancer index composite (EPIC) questionnaire. The quality-of-life scores will be converted to a scale of 0-100 for each category. A higher score indicates a better quality of life.

    Time frame: 2 years

  3. Urinary function using EPIC questionnaire

    Urinary function will be collected using expanded prostate cancer index composite (EPIC) questionnaire. The quality-of-life scores will be converted to a scale of 0-100 for each category. A higher score indicates a better quality of life.

    Time frame: 2 years

  4. Bowel function using EPIC questionnaire

    Bowel function will be collected using expanded prostate cancer index composite (EPIC) questionnaire. The quality-of-life scores will be converted to a scale of 0-100 for each category. A higher score indicates a better quality of life.

    Time frame: 2 years

  5. Assessment of adaptive RT approach using dose accumulation

    Dosimetric assessment of the CBCT-guided online adaptive RT approach using dose accumulation.

    Time frame: 2 years

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Apr 2029, 36 months after the start.

Of 295 non-industry interventional studies with no phase under Neoplasm Metastasis, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 93. This study's planned 36 months is below that.

Counting every sponsor, half of 320 studies reached it within 54 months; a quarter within 28 and three quarters within 91.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 20, 2026: start Jul 2026 → Apr 2026, primary completion Jul 2029 → Apr 2029 and completion Jul 2029 → Apr 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 13, 2025
First posted
Feb 17, 2025
StartActual
Apr 13, 2026was Jul 2026
Primary completionEst.
Apr 13, 2029was Jul 2029
CompletionEst.
Apr 13, 2029was Jul 2029
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Jul 7, 2026→Apr 13, 2026 (actual)
Oct 20, 2026
Primary completion
Jul 7, 2029→Apr 13, 2029
Oct 20, 2026
Study completion
Jul 7, 2029→Apr 13, 2029
Oct 20, 2026
Show all 1 update
  1. Oct 20, 2026
    Start date Jul 7, 2026→Apr 13, 2026 (now actual)
    Primary completion Jul 7, 2029→Apr 13, 2029
    Study completion Jul 7, 2029→Apr 13, 2029
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06831032
Responsible party
Sponsor
First posted
Feb 17, 2025
Start date
Apr 13, 2026
Primary completion
Apr 13, 2029 (estimated)
Completion
Apr 13, 2029 (estimated)
Last update
Oct 20, 2026

Study contacts

Andrew McPartlin, MD
Contact
andrew.mcpartlin@uhn.ca
416-946-4501 ext. 4855

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion